Dupixent (generic name: dupilumab) has been marketed as a breakthrough treatment for conditions like eczema, asthma, and chronic sinusitis with nasal polyps. However, recent reports have linked Dupixent to a serious and life-threatening type of cancer known as cutaneous T-cell lymphoma (CTCL). For patients and families affected, this news can be devastating.
If you or a loved one developed CTCL or another form of non-Hodgkin’s lymphoma after taking Dupixent, you may be eligible to file a Dupixent lawsuit and pursue compensation. The experienced attorneys at Riddle & Riddle Injury Lawyers are here to help. Call (919) 876-3020 today for a free, no-obligation consultation.
Our Dupixent lawsuit lawyers have secured millions of dollars in compensation for deserving injury victims since 1985 (see disclaimer below), and we’re ready to help however we can. Please call (919) 876-3020 and let’s review your claim for free.
December 2025 Update
The Dupixent lawsuits involving cutaneous T-cell lymphoma (CTCL) continued to expand through December 2025, as plaintiffs allege that the medication Dupixent (dupilumab)—commonly prescribed for eczema, asthma, and chronic rhinosinusitis—may trigger, accelerate, or unmask CTCL, a rare but serious form of non-Hodgkin’s lymphoma. Patients report that symptoms initially attributed to severe eczema worsened while on Dupixent, only later being diagnosed as CTCL. Lawsuits argue that Regeneron and Sanofi failed to provide adequate warnings about this potential risk, even as case reports and dermatology literature began to describe a concerning pattern.
Recent developments include:
- A continued rise in national filings, particularly from individuals who used Dupixent for extended periods before receiving a CTCL diagnosis. Many describe delayed recognition of cancer due to symptom overlap with eczema.
- Growing attention to allegations that Dupixent may mask or accelerate CTCL progression, making early diagnosis more difficult and potentially allowing the cancer to advance before detection.
- Increased expert testimony preparation, with plaintiffs focusing on biologic mechanisms involving IL-4 and IL-13 pathway inhibition, arguing this may contribute to abnormal T-cell proliferation in susceptible patients.
- Renewed scrutiny of Dupixent’s labeling, as lawsuits claim the warnings minimize or omit meaningful discussion of CTCL risk, despite mounting anecdotal and clinical observations.
- Consolidation efforts in several state courts, with legal teams evaluating whether a federal MDL may be appropriate as filings continue to climb.
Overall, the Dupixent CTCL litigation is gaining traction, fueled by heightened awareness among dermatologists and patients and by emerging patterns in clinical case reports. The key factor to watch heading into 2026 is how courts evaluate expert causation evidence, which will ultimately determine the viability and scale of these claims.
What is Dupixent?
Dupixent (dupilumab) is a prescription medication manufactured by Sanofi and Regeneron. It is an injectable biologic approved by the FDA for treating:
- Moderate to severe atopic dermatitis (eczema)
- Moderate to severe asthma in adults and children ages 6 and older
- Chronic rhinosinusitis with nasal polyps
Dupixent works by targeting specific proteins involved in the body’s immune response, including interleukin-4 (IL-4) and interleukin-13 (IL-13). By blocking these proteins, the drug reduces inflammation that contributes to allergic diseases and skin conditions.
While Dupixent has helped many patients, serious safety concerns have been raised, including its potential link to cutaneous T-cell lymphoma (CTCL).
What is Cutaneous T-Cell Lymphoma (CTCL)?
CTCL is a rare type of non-Hodgkin’s lymphoma that primarily affects the skin. It begins in T-cells, a type of white blood cell that plays a key role in the immune system. Unlike most lymphomas, which occur in the lymph nodes, CTCL often presents as rashes, patches, plaques, or tumors on the skin.
Symptoms may include:
- Red, scaly, or itchy patches on the skin
- Thickened or raised skin lesions
- Enlarged lymph nodes
- Fatigue or unexplained weight loss
CTCL is a serious and potentially life-threatening cancer. Because it can initially resemble eczema or psoriasis, diagnosis is often delayed — and some reports suggest that Dupixent may mask symptoms of CTCL, leading to later diagnoses when the cancer is more advanced.
Dupixent and the Link to CTCL
Although Dupixent is approved to treat eczema and other inflammatory conditions, concerns have grown that it may trigger or accelerate cutaneous T-cell lymphoma in certain patients.
Key concerns include:
- Symptom overlap: CTCL can initially look like eczema, meaning patients treated with Dupixent for skin conditions may actually have undiagnosed cancer.
- Disease progression: Some case reports suggest Dupixent could worsen existing CTCL or accelerate its progression.
- FDA reports: Post-marketing surveillance data has revealed cases of CTCL and other lymphomas in patients treated with Dupixent.
While research is ongoing, these reports have raised alarms among patients and medical professionals.
Potential Compensation in a Dupixent Lawsuit
If you or a loved one developed cutaneous T-cell lymphoma after taking Dupixent, you may be entitled to financial compensation. A Dupixent lawsuit could help you recover damages for:
- Medical expenses (current and future treatment)
- Lost wages and reduced earning capacity
- Pain and suffering
- Emotional distress
- Wrongful death damages (if you lost a loved one due to CTCL after Dupixent use)
Our attorneys at Riddle & Riddle Injury Lawyers can help evaluate your case and fight for the compensation you deserve. Call (919) 876-3020 today for a free consultation.
Current Status of Dupixent CTCL Lawsuits
As of September 2025, Dupixent litigation related to cutaneous T-cell lymphoma is still in the early stages. Here are the latest developments:
- Individual lawsuits filed – Patients and families have begun filing claims alleging that Dupixent caused or accelerated CTCL diagnoses.
- No MDL yet – Unlike other mass tort drug cases, a formal multidistrict litigation (MDL) has not yet been created for Dupixent CTCL claims. However, attorneys are closely monitoring the growing number of cases to determine if consolidation may be requested.
- Ongoing investigations – Lawyers across the country are investigating potential claims on behalf of patients who developed CTCL after using Dupixent.
- Potential future MDL – If enough lawsuits are filed in federal courts, the Judicial Panel on Multidistrict Litigation (JPML) could consider consolidating them into a centralized MDL. This would streamline pretrial proceedings and discovery.
- Focus on failure to warn – Many of the emerging claims allege that Sanofi and Regeneron failed to adequately warn patients and healthcare providers about the risk of CTCL and other cancers.
If you or someone you love has been diagnosed with CTCL after using Dupixent, it is important to speak with an attorney as soon as possible to preserve your legal rights.
Who May Qualify for a Dupixent Lawsuit?
You may qualify to file a Dupixent lawsuit for CTCL if:
- You were prescribed Dupixent for eczema, asthma, or another approved condition
- You later developed cutaneous T-cell lymphoma (CTCL) or another type of non-Hodgkin’s lymphoma
Even if you are unsure whether your case qualifies, our attorneys can review your situation and provide guidance at no cost. Call (919) 876-3020 today for a free case review.
What to Do if You Were Diagnosed with CTCL After Taking Dupixent
If you believe Dupixent may have caused your cutaneous T-cell lymphoma, here are important steps you should take:
- Seek immediate medical care and follow your doctor’s treatment plan.
- Keep detailed records of your medical history, prescriptions, and symptoms.
- Save all medication packaging and receipts as evidence.
- Contact an experienced product liability lawyer as soon as possible to protect your rights.
Time limits apply to filing pharmaceutical injury lawsuits, so do not wait to seek legal guidance.
How Riddle & Riddle Injury Lawyers Can Help
At Riddle & Riddle Injury Lawyers, we are dedicated to holding pharmaceutical companies accountable when their products harm patients. We have successfully recovered over $900 million in compensation for clients since 2000, helping victims and their families rebuild their lives after serious injury (see disclaimer below).
Our attorneys bring more than 171 years of combined legal experience to every case. We have been recognized by prestigious organizations such as Super Lawyers and The National Trial Lawyers Top 100, reflecting our commitment to excellence in advocacy (see disclaimer below).
Here’s what one of our clients had to say:
“Every time I’ve needed them, they were there for me.” —Christine W.
When you work with our firm, you don’t pay any attorney fees unless we win your case. When Justice Counts™, we’re here to fight for you.
Why Riddle & Riddle for Your Dupixent CTCL Claim?
Choosing the right lawyer can make all the difference in your case. At Riddle & Riddle Injury Lawyers, we offer:
- Decades of experience – Over 171 years of combined legal experience fighting for injury victims.
- Proven results – More than $900 million recovered for clients across North Carolina and beyond.
- National recognition – Our attorneys have been honored by Super Lawyers, The National Trial Lawyers Top 100, and other respected organizations.
- Client-focused advocacy – We treat every client with compassion and respect, ensuring your voice is heard.
- No upfront costs – You only pay attorney fees if we recover compensation for you.
If you or a loved one has been diagnosed with cutaneous T-cell lymphoma after taking Dupixent, you may be entitled to justice and financial recovery. Call (919) 876-3020 today for your free consultation with an experienced Dupixent lawsuit attorney at Riddle & Riddle.
When Justice Counts™, we’re ready to help.